Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry
Overview
Authors
Affiliations
Purpose: To examine the California Cancer Registry (CCR) for bladder cancer survival disparities based on race, socioeconomic status (SES), and insurance in California patients.
Patients And Methods: The CCR was queried for bladder cancer cases in California from 1988 to 2012. The primary outcome was disease-specific survival (DSS), defined as the time interval from date of diagnosis to date of death from bladder cancer. Survival analyses were performed to determine the prognostic significance of racial and socioeconomic factors.
Results: A total of 72,452 cases were included (74.5% men, 25.5% women). The median age was 72 years (range, 18-109 years). The racial distribution among the patients was 81% white, 3.8% black, 8.8% Hispanic, 5.2% Asian, and 1.2% from other races. In black patients, tumors presented more frequently with advanced stage and high grade. Medicaid patients tended to be younger and had more advanced-stage, higher-grade tumors compared to patients with Medicare or managed care (P < .0001). Kaplan-Meier analysis demonstrated significantly poorer 5-year DSS in black, low SES, and Medicaid patients (P < .0001). When controlling for stage, grade, age, and gender, multivariate analysis revealed that black race (DSS hazard ratio = 1.295; 95% confidence interval, 1.212-1.384), low SES (DSS hazard ratio = 1.325; 95% confidence interval, 1.259-1.395), and Medicaid insurance (DSS hazard ratio = 1.349; 95% confidence interval, 1.246-1.460) were independent prognostic factors (P < .0001).
Conclusion: An analysis of the CCR demonstrated that black race, low SES, and Medicaid insurance portend poorer DSS. These findings reflect a multifaceted socioeconomic and public health conundrum, and efforts to reduce inequalities should be pursued.
Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy.
Ikhapoh I, Atairu U, Reich A, Mantia C, Wei X, Sekar R J Clin Med. 2025; 14(3).
PMID: 39941550 PMC: 11818695. DOI: 10.3390/jcm14030879.
Socioeconomic disparities in survival of patients with non-muscle invasive urothelial carcinoma.
Baralo B, Daniels P, McIntire C, Thirumaran R, Melson J, Paul A World J Urol. 2025; 43(1):120.
PMID: 39937268 PMC: 11821756. DOI: 10.1007/s00345-024-05422-2.
Kami Reddy K, Piyarathna D, Park J, Putluri V, Amara C, Kamal A JCI Insight. 2024; 9(17).
PMID: 39253977 PMC: 11385078. DOI: 10.1172/jci.insight.172336.
Escott M, Yi Y, Foret A, Li T, Hsieh M, Delacroix Jr S Cancer Med. 2024; 13(12):e7301.
PMID: 38923853 PMC: 11199337. DOI: 10.1002/cam4.7301.
Ladi-Seyedian S, Ghoreifi A, Konety B, Pohar K, Holzbeierlein J, Taylor J Cancers (Basel). 2024; 16(7).
PMID: 38610946 PMC: 11011163. DOI: 10.3390/cancers16071268.